Last reviewed · How we verify
Butamyrate (BUTAMIRATE)
Butamyrate (generic name: BUTAMIRATE) is a butamirate drug. It is currently in Phase 2 development.
Butamirate is thought to work by interacting with a specific target in the body, although its exact mechanism of action is unknown.
Butamirate is a small molecule. It is also known by the synonyms butamirate, butamirate, butamirate, butamirato, and codimin.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BUTAMIRATE |
|---|---|
| Drug class | butamirate |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine butamirate as a key that fits into a lock in the body. When it binds to this lock, it can affect how the body works, but we don't yet know exactly how it does this or what it does to help with a particular condition.
Approved indications
Common side effects
Key clinical trials
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- A Study of Butamirate Citrate Syrup Versus (vs) Sinecod Syrup (Vanilla) in Adult Healthy Study Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Butamyrate CI brief — competitive landscape report
- Butamyrate updates RSS · CI watch RSS
Frequently asked questions about Butamyrate
What is Butamyrate?
How does Butamyrate work?
What is the generic name of Butamyrate?
What drug class is Butamyrate in?
What development phase is Butamyrate in?
Related
- Drug class: All butamirate drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing